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Given thousands of proteins constituting a eukaryotic pathogen, the principal
objective for a high-throughput in silico vaccine discovery pipeline is to select those
proteins worthy of laboratory validation. Accurate prediction of T-cell epitopes on
protein antigens is one crucial piece of evidence that would aid in this selection.
Prediction of peptides recognised by T-cell receptors have to date proved to be of
insufficient accuracy. The in silico approach is consequently reliant on an indirect
method, which involves the prediction of peptides binding to major
histocompatibility complex (MHC) molecules. There is no guarantee nevertheless
that predicted peptide-MHC complexes will be presented by antigen-presenting
cells and/or recognised by cognate T-cell receptors. The aim of this study was to
determine if predicted peptide-MHC binding scores could provide contributing
evidence to establish a protein’s potential as a vaccine. Using T-Cell MHC class I
binding prediction tools provided by the Immune Epitope Database and Analysis
Resource, peptide binding affinity to 76 common MHC I alleles were predicted for
160 Toxoplasma gondii proteins: 75 taken from published studies represented
proteins known or expected to induce T-cell immune responses and 85 considered
less likely vaccine candidates. The results show there is no universal set of rules
that can be applied directly to binding scores to distinguish a vaccine from a non-
vaccine candidate. We present, however, two proposed strategies exploiting
binding scores that provide supporting evidence that a protein is likely to induce a T-
cell immune response–one using random forest (a machine learning algorithm) with
a 72% sensitivity and 82.4% specificity and the other, using amino acid
conservation scores with a 74.6% sensitivity and 70.5% specificity when applied to
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the 160 benchmark proteins. More importantly, the binding score strategies are
valuable evidence contributors to the overall in silico vaccine discovery pool of
evidence.
Introduction
An in silico protein-based vaccine discovery pipeline for eukaryotic pathogens,
inspired by reverse vaccinology [1–6], encapsulates a collection of various
bioinformatics prediction tools [7]. The aim of these tools is to gather
computational evidence, derived mainly from protein sequences, to select the
most promising vaccine candidates worthy of laboratory validation [8]. One piece
of evidence, considered crucial in the candidacy decision making, is the presence
of epitopes on protein antigens.
Many tools have been and are still being developed to computationally predict
epitopes (see S1 Supporting Information). T-cell epitopes, which are typically
short linear peptides, have proved to be easier to predict than B-cell epitopes [9–
11]. Currently, there are two computational approaches to T-cell epitope
prediction based on direct and indirect methods. A direct method predicts
peptides recognised by T-cell receptors, whereas an indirect method predicts
peptides binding to MHC molecules. Direct methods, as to date, have proved to
be of insufficient accuracy [9] and this may be why the majority of T-cell epitope
predictors currently found online are based on indirect methods. This paper
focuses on the indirect method and the MHC class I molecule.
Most vaccines licensed so far are serum antibody-based that essentially provide
protection from infection. Current opinion suggests that T-cell epitope ‘only’
vaccines are not a solution to prevent infection, but are important in controlling
an established infection by the recognition and clearance of infected cells [10]. For
many infectious diseases (and cancers) it remains an open question if cell-
mediated immunity (CMI) is required for successful prevention or eradication,
either in addition to or instead of antibodies [11].
The foremost resource for T-Cell MHC class I binding prediction tools is
provided by the Immune Epitope Database and Analysis Resource (IEDB) [12].
The MHC class I binding predictor (referred henceforth as the peptide-MHC
binding predictor) takes as input an amino acid sequence (or a set of sequences)
and predicts the binding affinity of each fixed-length subsequence to a specific
MHC molecule. Fig. 1 shows an example of the online output. S1 Supporting
Information describes the prediction process in detail including the methods used
for computation.
The desired aim, from an in silico vaccine discovery perspective, is to use
binding affinity scores as contributing evidence to a pool of other computationally
derived evidence and, at this stage, not to specifically identify epitopes for vaccine
development. The pool of evidence, in this instance, is ultimately used to support
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or oppose a protein as a candidate for a CMI-driven vaccine. Two important
issues need to be emphasised here. First, there is no guarantee that a protein
predicted to contain peptides that bind to a particular MHC allele will be
presented by antigen-presenting cells and/or recognised by cognate T-cell
receptors. Consequently, binding scores are only one piece of evidence and need
to be used in conjunction with other gathered evidence as part of an overall
vaccine candidate discovery strategy. Second, there are potentially thousands of
proteins, mostly uncharacterised, constituting a pathogenic microorganism. An in
silico discovery strategy demands an automated high-throughput process to
extract evidence as it is impractical for a researcher to perform a case-by-case
examination of each protein.
There are potentially thousands of pathogenic organisms for which vaccines are
needed to improve human and animal health. Whilst advances in reverse
vaccinology have begun to provide vaccines for prokaryotic pathogens [13–17],
similar advances for eukaryotic pathogens such as parasites cannot be claimed.
Toxoplasma gondii, a protozoan parasite and important model system for the
phylum Apicomplexa [18–20], was chosen in this study to illustrate the presented
strategies. The first main reason for choosing T. gondii is that the indirect
prediction method is dependent on experimentally validated peptide-MHC
binding data from the host of the target pathogen. Humans are the intermediate
host for T. gondii in which it is responsible for birth defects and foetal loss [21].
Data for human MHC alleles, referred to as human leukocyte antigen (HLA), is by
far the most abundant. The peptide-MHC binding predictor makes available 2947
MHC I alleles but distinguishes 76 of these alleles as commonly occurring in at
least 1% of the human population (18 HLA-A, 32 HLA-B, 20 HLA-C, 1 HLA-E, 5
HLA-G). The second reason is that a large body of literature suggest that because
T.gondii is an intracellular parasite, the most important correlate of protection is
Fig. 1. Example of online output from IEDB peptide-MHC class I binding predictor. The binding predictor conceptually slides a window of a user-
defined length (either eight to eleven amino acid residues) one residue at a time from the start of the protein sequence. An affinity score is predicted for the
ability of each fixed-length subsequence (as defined by each position of the sliding window) to bind to a user-specified MHC I allele. Fig. 1 shows the output
when a sequence (e.g. MARHAIFFALCVLGL…) is input into the program to predict if it contains peptides of length 9 that bind to the MHC allele, HLA-
A*11:01. The IC50 (nM) affinity scores for subsequence ‘MARHAIFFA’ at position 1 to 9 are highlighted.
doi:10.1371/journal.pone.0115745.g001
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the induction of a CMI response (this is in addition to a humoral response)
[22–26].
Predicted binding scores alone provide no direct indication of a protein’s
potential to induce a T-cell response. The aim of this study is therefore to
determine how these scores can best be utilised to provide such an indicator. We
present two high-throughput classification strategies. Ideally, two types of protein
examples are required to credibly demonstrate and test the strategies: proteins that
are known to generate a T-cell response in the host (positives) and those known
not to generate a response (negatives). The challenge for obtaining reliable
positives is that there is no known example of an effective T-cell based vaccine,
and even no clear consensus as to what type of protein constitutes an ideal vaccine
candidate for a T-cell mediated response. Furthermore, no distinguishing signal
within a protein sequence has been detected that indicates a protein not only
contains T-cell epitopes but also induces an immune response. The challenge for
negative examples is that a protein cannot be definitively negative unless it has
been explicitly tested for non-inducement against all common MHC alleles. To
face these challenges, the test and training proteins selected for the study are the
optimum within the constraints of available data and current knowledge. For
example, in the absence of what constitutes an ideal vaccine candidate, the
selected proteins are only likely vaccine candidates – ‘likely’ in this context is
based on a priori held hypotheses that a protein that is either external to or located
on, or in, the membrane of a pathogen is more likely to be accessible to
surveillance by the immune system than a protein within the interior of a
pathogen [27]. Also, the majority of proteins in published studies observed to
induce T-cell responses are membrane-associated or secreted [22, 28–34]. A few
examples of proteins with annotated interior subcellular locations, nevertheless,
have been observed to induce an immune response [33], which confounds the
search for a typical T-cell inducing protein. To summarise, proteins naturally
exposed to the immune system are considered in this study as potential vaccine
candidates or positives, and unexposed proteins as non-vaccine candidates or
negatives.
The first proposed strategy uses random forest, a supervised machine learning
(ML) algorithm. The algorithm essentially detects patterns within a series of
binding scores that are computed for the entire length of each protein. Quality
examples of binding scores from positive and negative proteins are the key to the
strategy i.e. they are required to train the ML algorithm. Once trained, the
algorithm can distinguish likely vaccine or non-vaccine candidates given a new
series of binding scores from an anonymous protein.
The second proposed strategy uses amino acid conservation scores of predicted
binding peptides and is based on the principle that eukaryotic pathogens have
evolved with the vertebrate immune system [35]. More specifically, amino acids of
T. gondii proteins can change over time under the evolutionary selection pressure
of the human immune system. For example, human HLA alleles evolve to
optimise fitness and T. gondii antigens adapt to evade HLA capture. Amino acid
residues that are vital to a protein’s function tend to be the most highly conserved
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in homologous proteins as they change less rapidly during evolution. This means
that T. gondii antigens are in an evolutionary balancing act to evade the immune
system by varying their antigens but still retaining functionality. It is suggested
that immune evasion is achieved by changes at multiple sites rather than
clustering polymorphisms at one site [36]. In other words, amino acid sites in a
protein antigen are expected to be under different selection pressures and their
conservation will vary accordingly. There are examples of apicomplexan proteins
where amino acids exposed to the immune system are more polymorphic than
those unexposed [37–39]. We speculate that binding peptides will be located more
often in less conserved sites. However, from an epitope-based vaccine perspective,
conserved epitopes are more desirable to provide broad protection across multiple
strains [40]. A multiple sequence alignment (MSA) can be used to compare amino
acid similarity between a protein and its homologues [41]. The degree of residue
conservation is inferred from the similarity within an aligned column. Various
methods have been developed to quantitatively score the conservation and are
compared in a review [42]. Our strategy compares conservation scores of
predicted binding peptides to distinguish between potential vaccine or non-
vaccine candidates.
We conclude that there is no single program that can predict proteins that will
elicit T-cell immune responses. The current best approach is to obtain a consensus
from several programs to select those proteins ‘most likely’ to induce the required
response. The results obtained from the ML and conservation strategies are not
perfect owing to constraints posed by the programs and available data.
Nevertheless, the strategies still provide valuable evidence towards a consensus.
Currently, there is no known alternative solution for using binding scores in a
high-throughput approach to identify vaccine candidates.
Results and Discussion
The first important question to answer was how accurate are the IEDB peptide-
MHC class I binding predictions. Our results from an affinity-strength accuracy
test revealed a sensitivity and specificity of 63.1% and 78.9% respectively. This
indicates that the predictor has a relatively low sensitivity in predicting precise
affinity strength. It has a greater sensitivity, however, to high-affinity peptides (e.g.
80.1%) than intermediate (45.4%) or low affinity (35.5%) peptides. The accuracy
to predict binding or non-binding peptides, irrespective of affinity strength, was
91.7%. Other studies also report that the predictions are good, particularly for
well-studied class I MHC alleles [43, 44].
Binding studies show that HLAs are the most polymorphic human genes
known [45] and each HLA allele recognizes a restricted set of peptides [46]. Our
results from a binding test on the entire known proteome of T. gondii (including
different strains) were therefore not totally unexpected given the known
polymorphic nature of MHC: 19355 out of 19378 proteins tested contained at
least one high-affinity binding peptide. No predictions were made for 23 proteins
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as their sequence contained characters such as ‘X’ or ‘B’, which are non-standard
to the amino acid single letter code and invalid to the predictor. To support this
finding, binding predictions were analysed from 124 proteins from Plasmodium
falciparum (an apicomplexan that can cause malaria) and 760 proteins from
Caenorhabditis elegans (a non-pathogenic nematode). The important conclusion
inferred from these results is that every protein from a eukaryotic pathogen is
predicted to contain at least one peptide that binds with a high-affinity to at least
one of the known human MHC I alleles. Given this finding, it is impracticable to
select a protein for vaccine candidacy on the basis it contains a high-affinity
peptide.
The output from the binding predictor are potentially thousands of IC50 (nM)
scores for each protein under consideration. Table 1 shows descriptive statistics
for predicted high-affinity peptides from the species T. gondii, P. falciparum, and
C. elegans. The number of peptides range for T. gondii from five to 3768 per
protein and each protein can contain peptides that bind to as few as six and to as
many as 137 different allele-peptide length combinations.
Results for rule-based classification
Rule-based tests were performed on a benchmark dataset to differentiate ‘YES’
from ‘NO’ vaccine candidates. That is, binding scores were ordered on different
statistical properties of the score and then appropriate test thresholds applied to
perform a binary classification. S2 Supporting Information lists the benchmark
proteins along with a publication reference to the relevant study and provides a
brief description of the vaccine significance for some of these proteins. Fig. 2
shows an example of the rule based-approach. The premise was to formulate
decision making rules that could be applied to scores from anonymous proteins
for the purpose of vaccine classification. The results are shown in Table 2.
Accuracy around 50% is no better than guesswork in binary classifications with
equally likely classes. Some of the rules showed promise but failed when applied to
different datasets. These results suggest that both vaccine and non-vaccine
candidates contain high-affinity binding peptides, peptides that bind to the same
MHC allele, have similar numbers of binding peptides and promiscuous peptides
per protein, and also have similar numbers of peptides that bind to promiscuous
MHCs. The important conclusion here is that there is no universal set of rules that
can be applied directly to binding scores to distinguish a vaccine from a non-
vaccine candidate.
Results from supervised machine learning classification
The best classification result achieved using random forest when trained on
apicomplexan proteins was 72% sensitivity (SN) and 82.4% specificity (SP) with a
22.5% overall error rate. These results have the potential to improve when more
training examples become available for proteins observed to induce, ideally
protective, T-cell responses. Fig. 3 illustrates a training dataset. Table 3 shows
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results for all tests conducted with random forest. These results suggest that
predictions improve when the source of training data is more closely related to the
target pathogen. Additional tests were performed to determine if these promising
results were achieved by chance. The value for the target variable (e.g. 1 or 0) in
Table 1. Descriptive statistics for predicted high-affinity peptides against 76 common human MHCs.
Description
Benchmark
Proteinsa P. falciparum C. elegans T. gondii proteome
Number of proteins tested 160 124 760 19378
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Abbreviations: P. falciparum5 Plasmodium falciparum, C. elegans5 Caenorhabditis elegans, T. gondii5 Toxoplasma gondii, H5 highest, L5 lowest, A5
average, Max 5 maximum, Min 5 minimum, SMM 5 stabilized matrix method, ANN 5 artificial neural network.
aBenchmark Proteins are proteins from published studies with known or expected T-cell responses (source species: T. gondii).
doi:10.1371/journal.pone.0115745.t001
Fig. 2. Example of rule-based approach applied to highest affinity peptide on each test protein.
Proteins are listed in ascending order based on the lowest IC50 (nM) binding affinity score. A threshold value
e.g. 1.5 is applied to the score to segregate the list into two classifications. Below the threshold is ‘YES’ for
vaccine candidacy and above is ‘NO’. The rule-based classification is compared with the expected
classification to determine performance accuracy. Threshold value is derived from a trial-and-error approach
with the intention to classify the greatest number of true positives and negatives.
doi:10.1371/journal.pone.0115745.g002
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the training datasets was randomly set for each protein and the same tests were
performed as before. The predictions, as shown in Table 3, are considerably less
accurate, which supports the conjecture that there is a relationship between scores
and target variable.
Table 2. Sensitivity and specificity for rule-based tests applied to high-affinity peptide-MHC binding scores for vaccine classification.







SN SP SN SP SN SP
1 Lowest IC50 score per protein 1.5 42.7 45.8 69.8 32.0 60.9 38.3
2 Number of high-affinity peptides per protein 200 64.0 61.2 42.4 80.0 28.4 68.9
3 Number of different MHC alleles per protein binding to
high-affinity peptides
74 56.0 63.5 43.8 79.2 25.5 73.5
4 Maximum number of high-affinity peptides per protein
binding to a particular MHC allele-peptide length combination
10 66.7 58.2 47.9 69.4 37.3 65.3
5 Total binding score per protein 32289 61.3 61.2 58.9 72.0 36.8 59.1
6 Groups: one with proteins containing peptides binding to
promiscuous MHCs; one with proteins containing peptides
NOT binding to promiscuous MHCs
Not applicable 47.2 44.5 45.2 48.3 47.2 45.3
Abbreviations: P. falciparum 5 Plasmodium falciparum, C. elegans 5 Caenorhabditis elegans, T. gondii 5 Toxoplasma gondii, SN 5 sensitivity (%) 5 true
positives/(true positives+false negatives), SP 5 specificity (%) 5 true negatives/(true negatives+false positives).
aProteins ordered on statistical property and test thresholds applied to perform a binary classification.
bThreshold derived from a trial-and-error approach, using the mean as a seed threshold, on benchmark proteins to achieve the greatest number of true
positives and negatives. Same universal rule (i.e. threshold) is applied to P. falciparum and C. elegans data.
cBenchmark Proteins are proteins from published studies with known or expected T-cell responses (source species: T. gondii).
doi:10.1371/journal.pone.0115745.t002
Fig. 3. Example file format of training dataset used in machine learning. There is one protein per line that
consists of the total binding affinity score for each peptide-MHC length combination e.g. 304 combinations for
76 common MHC I alleles (MHC I binds to peptides, typically eight to eleven amino acid residues in length.
Therefore, 76 alleles * 4 peptide lengths 5304 combinations). Binding affinity score 5 an IEDB IC50 (nM)
score ,5000. Each score is weighted by the length of the protein. The scores represent input variables or
predictors. The last column is a 1 or 0 that indicates an expected ‘YES’ or ‘NO’ vaccine candidacy and
represents the target variable. This expectation is based on the subcellular location annotation associated
with the protein in UniProtKB (secreted or membrane-associated 51, internal location 50).
doi:10.1371/journal.pone.0115745.g003
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Using randomforest and predict has the advantage that it outputs an estimated
probability for each protein of belonging to ‘YES’ and ‘NO’ classes e.g. for
UniProt ID ‘A4GWX7’, 19.6% for ‘NO’ and 80.4% for ‘YES’ class. These
probabilities can be used to rank the candidates. The probabilities in effect
encapsulate all peptide-MHC binding scores from a protein and represent the
predicted vaccine candidacy potential. A caveat here is that a protein assigned a
high ‘YES’ probability does not necessarily imply a high probability of an immune
response when injected in a host. However, it is assumed a high probability
protein is more likely to contain the appropriate binding peptides to the restricted
set of host MHC alleles than one with a lower probability.
Results from amino acid conservation classification
It is arguable whether the proposed ML strategy is only indirectly predicting
secreted and membrane-associated proteins owing to the nature of the training
data. Several secreted and membrane-associated proteins with no known
immunogenicity history were also tested with the ML strategy. The challenge is
that there is no way of validating, other than testing in a wet laboratory, if proteins
with predicted low probabilities are truly non-vaccine candidates. The second
proposed strategy, using amino acid conservation scores, requires no training data
and independently supplements the ML strategy. Fig. 4 shows a plot of the
conservation scores computed for a sliding window of nine amino acids in length
along a protein. A window in this instance represents the length of a peptide. The
general shape of the plot is typical for all proteins whereby some regions are more
conserved than others. A binding score at each window/peptide against the 76
common alleles was predicted. Binding peptides with varying affinity strengths
were typically found along the entire length in all tested proteins, as is the case in
Fig. 4. The binding peptide distribution is also in keeping with the expected
Table 3. Sensitivity and specificity for random forest tests applied to peptide-MHC binding scores for vaccine classification of Benchmark dataset.
Training dataset Cross-validationa Benchmarkb
SN SP HE SN SP OE
Plasmodium falciparum 75.0 85.6 20.0 77.3 50.6 36.9
Plasmodium falciparum (R) 38.9 61.7 49.7 58.2 49.7 54.2
Caenorhabditis elegans 63.4 57.5 39.4 36.0 56.5 60.0
Caenorhabditis elegans (R) 55.4 48.3 51.6 52.4 56.4 54.3
Apicomplexans 86.7 80.7 16.1 72.0 82.4 22.5
Apicomplexans (R) 54.0 38.2 42.9 74.0 39.0 42.5
Abbreviations: (R)5 target variable e.g. 1 or 0 in training data randomly changed for each protein, HE5 hold-out dataset error (%) i.e. error when predicting
30% of training data, OE 5 overall error (%) i.e. percentage of incorrect predictions, SN 5 sensitivity (%) 5 true positives/(true positives+false negatives),
SP 5 specificity (%) 5 true negatives/(true negatives+false positives).
aCross-validation involved a random sample of 70% from training dataset to build predictive model and remaining 30% used for testing. This was repeated
10 times and predictions averaged (predictions for the same input data fluctuate unless a random seed is set initially).
bBenchmark are proteins from published studies with known or expected T-cell responses (source species: T. gondii) –100% from training data used to build
predictive model.
Note: Number of input variables used to build predictive model 5304 (i.e. number of allele-peptide length combinations derived from 76 common alleles).
doi:10.1371/journal.pone.0115745.t003
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biology. That is, epitopes are expected to naturally occur in both conserved and
non-conserved regions. The aim of the second strategy was to correctly classify
each benchmark protein given only its collection of binding and associated
conservation scores. Three techniques (described later in Materials and Methods)
were used with varying degrees of success. The classification results were: SN
574.6% and SP 570.5% (when using mean difference as a threshold); SN
570.7% and SP 572.9% (with mean threshold); and SN566.7% and SP564.7%
(with cumulative counts). All three techniques use a threshold for the binary
classification that can be adjusted giving a trade-off between the two performance
measures. Moreover, as with any threshold technique, prediction values close to
the threshold warrant further evidence to support the classification. Despite the
fluctuating results, the important finding is that there is a statistically significant
relationship between a potential vaccine candidate and the conservation of its
amino acids. That is, a vaccine candidate is significantly more likely to have either
a greater number of less conserved peptides and/or a lower total conservation
score than a non-vaccine candidate (Pearson’s Chi-squared test with Yates’
continuity correction: p-value ,0.001). To further eliminate the possibility that
Fig. 4. Plot of conservation scores computed for binding peptides along a protein (UniProtKB ID: P13664). Each circle represents the amino acid
conservation score computed at a sliding window. The window is of length 9 and slides one residue at a time. The colour of the circle represents binding
affinities against 76 common MHC alleles computed at each window. A window (i.e. a peptide) can theoretically bind to all 76 alleles and colours are
therefore plotted in a set order: no, low, intermediate, and high affinity. For example, a dark blue circle for low affinity indicates there are no intermediate or
high affinity peptides at the window; however, a green circle for high affinity provides no indication of other affinities at the same window. Mean conservation
50.7805; median conservation 50.7946. For protein P13664 (Major surface antigen p30) 54.6% high, 56% intermediate, and 55.9% low binders have
conservation scores below the mean. The study shows that vaccine candidates are significantly more likely to have either a greater number of less
conserved peptides or a lower total conservation score than non-vaccine candidates.
doi:10.1371/journal.pone.0115745.g004
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the results were achieved by chance, the conservation scores were randomly
shuffled and associated with a different binding score. That is, the average mean
conservation for the protein remained the same but the association between the
binding and conservation scores were random. In this instance, the classification
results using mean difference as a threshold were: SN552.7% and SP547.9% (p-
value 51).
Comparison to other high-throughput prediction programs
There are alternative programs to the proposed peptide-MHC strategies as the
framework for what constitutes a vaccine candidate in this study is essentially
based on subcellular location. Five high-throughput programs (WoLF PSORT
[47], SignalP [48], TargetP [49], TMHMM [50], and Phobius [51]) were used
with protein sequences from the benchmark proteins as input. These programs
predict protein characteristics relevant to subcellular location but in particular
provide computationally evidence a protein is secreted or membrane-associated
i.e. they can support or oppose a protein as a vaccine candidate. Fig. 5 shows a
column chart as a comparison of the programs’ performances in classifying
membrane-associated or secreted (S3 Supporting Information contains the exact
predicted values). No program on its own provides sufficient evidence to draw
conclusions for vaccine candidacy. Notwithstanding the inaccuracies of the
programs, only WoLF PSORT can predict both membrane and secreted proteins.
The presented strategies are also compared in Fig. 5. They compare favourably in
distinguishing between immune exposed/unexposed proteins but do not
differentiate the subcellular location. The crucial point nevertheless is that only
some of the proteins predicted by the five programs will contain appropriate
binding peptides to the restricted set of host MHC alleles. The peptide-MHC
strategies can help determine these proteins. They are therefore not intended to
compete but complement other evidence gathering programs. It is expected that
an informed consensus towards candidacy will always be derived from multiple
sources of evidence.
The core of the strategies is protein sequences. It is possible that linear
sequences simply lack sufficient information to precisely predict immunogenicity.
Peptide-MHC complexes and T-cell receptors are dynamic three-dimensional
(3D) structures such that structure-based information is expected to more likely
reveal signals for immunogenicity. These signals theoretically can be predicted.
However, a virtual absence of apicomplexan structural data presently rules out a
structure-driven approach. The proposed strategies provide a worthwhile interim
approach until 3D data and appropriate new prediction strategies become readily
available.
Utilising Peptide-MHC Binding Scores for In Silico Vaccine Discovery
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Conclusion
The aim of this study was to determine whether predicted peptide-MHC I binding
scores for thousands of proteins from a target pathogen could contribute evidence
to the in silico discovery of vaccine candidates. Currently there is no published
high-throughput approach for utilising such scores. An initial challenge to the
study was that there is no clear consensus as to what type of protein constitutes an
ideal vaccine candidate for a T-cell mediated response. Consequently, this study
defined a likely vaccine candidate as a protein that is naturally exposed to the
immune system and contains binding peptides to common host MHC alleles; and
conversely, a non-vaccine candidate as an unexposed protein.
The two presented peptide-MHC classification strategies can provide reason-
able evidence in comparison to alternative approaches but are faced with several
performance limiting sources of error. For example, an unknown percentage of
input sequences are incorrect leading to reduced binding and conservation
prediction accuracy. Similarly, an unknown percentage of annotation is incorrect
Fig. 5. Performance comparison between high-throughput subcellular location predictors and peptide-MHC binding strategies. A column chart
showing the sensitivity (SN) and the specificity (SP) performance measures for high-throughput programs in classifying 160 benchmark proteins as either
membrane-associated or secreted. Predictors for membrane 5 TMHMM, Phobius TM, and WoLF PSORT; predictors for secreted 5 Phobius SP, SignalP,
TargetP, and WoLF PSORT. Threshold criteria applied to each program’s specific output to achieve binary classification: TMHMM – membrane if
tmhmm_ExpAA .18$$; Phobius TM – membrane if number of transmembrane domains .0; Phobius SP – secreted if value 5 ‘Y’; SignalP – secreted if
SignalP_D.0.5; TargetP – secreted if value.0.5; WoLF PSORT – membrane if score.16$$ and annotation5 ‘membrane’, or secreted if score.16$$ and
annotation 5 ‘secreted’ (where $$ is a value recommended by the creator of the program). Machine learning 5 strategy using random forest algorithm with
peptide-MHC binding scores. Conservation 5 strategy using amino acid conservation of predicted binding peptides. Performance measures for peptide-
MHC strategies are derived from classification of benchmark proteins as either vaccine or non-vaccine candidates.
doi:10.1371/journal.pone.0115745.g005
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leading to misclassification for both test and training data. Furthermore, the
prediction programs used have their own inherent inaccuracies. The expectation
is that performances will improve as the quality of data inevitably improves over
time. However, the strategies, even with perfect programs and data, are unlikely to
ever reach perfection given the unpredictability of the biology in question. That is,
both immune-exposed and unexposed proteins are likely to contain high affinity
binding peptides and/or many binding peptides and/or promiscuous binders and/
or peptides that bind to promiscuous MHCs, and conserved and non-conserved
peptides. There is no universal set of rules that can be applied directly to binding
scores to classify candidates. The strategies therefore rely on exploiting subtle
tendencies in the data to achieve their classification of candidates as there is yet no
definitive feature to precisely separate them. For instance, vaccine candidates have
a tendency to have more binding peptides with low conservation scores and/or
lower total conservation scores and/or average stronger binding affinities than
non-vaccine candidates. False candidates are expected since exposed proteins
containing binding peptides with predominantly high conservation scores and/or
average weak binding affinities do exist; and conversely, unexposed proteins exist
that contain binding peptides with predominantly low conservation scores and/or
average strong binding affinities. An important point in the strategies’ favour is
that the alternative approaches discussed only predict immune-exposed or
unexposed proteins and do not take peptide binding affinities into account. The
alternative approaches still require a filtering strategy otherwise every predicted
exposed protein would require laboratory validation. The proposed strategies can
contribute filtering evidence to the overall in silico vaccine discovery pool of
evidence to help identify those proteins more worthy of validation. This ultimately
will save time and money by reducing the number of false candidates assigned for
validation. Random forest especially provides evidence in the form of an
estimated probability for ranking candidates.
Materials and Methods
Six groups of tests were performed: 1) Accuracy test on peptide-MHC binding
predictor, 2) MHC class I binding test on the entire known proteome of T. gondii,
3) rule-based test, 4) comparison test with existing high-throughput programs
that can indicate a protein’s subcellular location, 5) machine learning test, and 6)
binding and conservation score test. Tests three to six are primarily for vaccine
candidate classification. All tests that required binding scores used a Linux
standalone version of the IEDB MHC I binding tools downloaded from http://
tools.immuneepitope.org/main/html/download.html. Consensus [52, 53] was the
chosen prediction method, which is the recommendation by the program
providers. This method consecutively uses several prediction methods. For
example, for each MHC allele and peptide length combination, the artificial
neural network (ANN) method [54] is tried first, stabilized matrix method
(SMM) [55] is tried next, and then scoring matrices derived from combinatorial
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peptide libraries (Comblib_Sidney2008) [56], and finally NetMHCpan [57] is
tried if no previous method was available for the allele-length combination.
Accuracy test on peptide-MHC binding predictor
The National Center for Biotechnology Information (NCBI) GI number for the
parent proteins of 328 experimentally derived T. gondii peptides were obtained
from the Immune Epitope Database (http://www.iedb.org/): 148 of these peptides
were observed in published studies to bind to specific MHC I alleles with a
measured affinity, and the remaining 180 peptides observed not to bind to MHC I
alleles. The parent protein sequences were downloaded from NCBI for input to
the peptide-MHC binding predictor. An in-house Perl script compared the
observed affinity strength of each peptide to a particular MHC allele with the
predicted affinity strength to the same allele.
MHC class I binding test on the entire known proteome of T. gondii
The protein sequence for every T. gondii protein from the Universal Protein
Resource knowledgebase (UniProtKB) was input into the peptide-MHC binding
predictor. The purpose was to predict the peptides binding to the 76 common
MHC I alleles (in effect, each protein was tested against 304 MHC allele-peptide
length combinations). An in-house Perl script parsed the output to determine
which proteins contained high-affinity peptides (i.e. IC50 (nM) binding score
,50).
Rule-based test for vaccine candidate classification
Protein sequences for 160 T.gondii proteins (75 positives and 85 negatives) were
downloaded from UniProKB: 22 of the positive proteins have been observed to
induce CMI responses and 48 have been experimentally shown to be membrane-
associated or secreted; 11 have epitopes identified experimentally and some of
these epitopes elicit significant humoral and cellular immune responses in
vaccinated mice. The 85 negative proteins have UniProtKB annotated subcellular
locations other than membrane-associated or secreted. All 160 proteins are
referred to in the study as the benchmark dataset (see S2 Supporting
Information).
The protein sequences were input into the peptide-MHC binding predictor to
test for their binding affinity to the 76 common human MHC I alleles. This
produced a binding score at each subsequence (i.e. a sliding window position
along the sequence) of each protein and for each of the 304 MHC allele-peptide
length combinations. More than one score can be output per subsequence when
using the Consensus method.
Proteins were ordered and classified on: Lowest IC50 score per protein
(threshold value 51.5), number of high-affinity peptides per protein (threshold
value 5200), number of different MHC alleles per protein that bound to high-
affinity peptides (threshold value 574), maximum number of high-affinity
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peptides per protein that bound to a particular allele-peptide length combination
e.g. protein Q6W3D0 was predicted to contain 58 high-affinity peptides that
bound to the same allele (HLA-C*03:03) with the same peptide length of 8
(threshold value 510), and total binding score per protein weighted for the length
of protein (threshold value532289). Another test involved grouping proteins that
had high-affinity peptides that bound to the same MHC allele or allele-peptide
length combination (i.e. promiscuous allele). This test was to determine if ‘YES’
candidates had preference to one particular allele and ‘NO’ candidates to another.
The same rules (i.e. threshold values) used for the benchmark dataset were
applied to binding scores computed from 124 P. falciparum and 760 C. elegans
protein sequences. These proteins were from a mixture of sub-cellular locations
(half have UniProt annotation as secreted or membrane-associated and
considered likely vaccine candidates; the other half have annotation related to
nuclear and cytoplasmic locations and considered less likely vaccine candidates).
Machine learning test for vaccine candidate classification
Three training datasets were created derived from: 1) 187 proteins from five
different pathogenic species of the phylum Apicomplexa (T. gondii, N. caninum,
P. falciparum, Cryptosporidium parvum, Eimeria tenella), 2) 760 proteins from C.
elegans, and 3) 124 proteins from P. falciparum. Protein sequences were
downloaded from UniProtKB. These sequences were consecutively input into the
peptide-MHC binding predictor to generate binding scores against 304 allele-
peptide length combinations per protein for each dataset. An in-house Perl script
parsed the output and added the binding score (i.e. IC50 (nM) ,5000) computed
for each peptide-MHC length combination to obtain a total binding score per
combination. The total score was divided by the length of the protein as there is a
strong positive correlation between the total and length. An average score was
computed if the output contained more than one score at each sliding window
position. A separate file for each training dataset was compiled in a format as
shown in Fig. 3. Note that other variations of the binding score statistics were
tested as training data: lowest IC50 score for each peptide-MHC length
combination, number of binding peptides per protein, number of different MHC
alleles per protein binding to high-affinity peptides, and total binding score
without length weighting. Proteins were selected based on subcellular location
annotation in UniProtKB, although experimentally validated annotation is limited
for T. gondii. Proteins from apicomplexan species that are known not to infect
humans (e.g. E. tenella) were included to increase the number of training proteins.
This seemed a reasonable approach, as the phylum Apicomplexa is monophyletic
[58] and many of the biological processes and molecules possessed by T. gondii
can also be found in other closely related species [19, 20]. Immune-exposed
proteins were assigned ‘1’ as the target variable; unexposed assigned ‘0’.
The same benchmark dataset as per the rule-based test was used. However, the
predicted binding scores for the 304 allele-peptide length combinations were
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compiled into the same format as Fig. 3, except no target variable column was
required.
Two supervised machine learning algorithms were used via R functions from
packages to build predictive classification models: random forest via the
randomForest R function [59]; and support vector machines (SVM) via the ksvm R
function [60], which is contained in the kernlab package. The best result for SVM
was a sensitivity of 68.2%, specificity 73.1%, and an overall error rate of 29.6%.
Random forest was chosen as the best method overall for solving this specific
classification problem because it had an overall error rate of 22.5%. The predict R
function with argument ‘type 5 ‘‘prob’’’ was used to apply the models to the
benchmark dataset. The argument instructs the output to have a class probability
distribution at each terminal node (or leaf) rather than a single ‘YES’ or ‘NO’ class
label. A threshold of greater than or equal to 0.5 for a vaccine candidate was used
in the final classification of the benchmark proteins. The algorithm-specific R
functions are described in S1 Supporting Information and pertinent arguments
and intricacies are highlighted.
Conservation and binding scores test for vaccine candidate
classification
A standalone BLASTP [61] on NCBI nr database was used with the benchmark
proteins as queries. BLAST downloaded from ftp://ftp.ncbi.nlm.nih.gov/blast/db/
ncbi-blast-2.2.25+-ia32-linux.tar.gz and nr downloaded from ftp://ftp.ncbi.nlm.
nih.gov/blast/db/. Homologous proteins with a 90% identity were selected from
the BLASTP output. Amino acid conservation scores were computed for peptides
of length nine to eleven for the entire length of each benchmark protein. For
example, for a peptide length of 9, a conservation score was computed for 9 amino
acids at a time sequentially moving one amino acid along the protein (i.e. a sliding
window). This involved generating MSAs for each window/peptide with the
homologous proteins and then computing an average conservation score for the
peptide. Two standalone programs were used: clustal-omega (http://www.ebi.ac.
uk/Tools/msa/clustalo/) for the MSAs and a conservation score program from
http://compbio.cs.princeton.edu/conservation. Each peptide-MHC binding score
for the 304 MHC allele-peptide length combinations were associated with the
appropriate conservation score. To help visualise the data refer to Fig. 4. Three
different counting classification techniques were applied to the data with the aim
to obtain the optimum number of true positives and negatives: 1) using a mean
threshold – if the binding peptide had a conservation score below the protein’s
mean conservation then the ‘YES’ tally was increased by one, otherwise the ‘NO’
tally was increased by one (the median, which was extremely similar in value to
the mean, was also used as a threshold but gave slightly poorer results); 2) using a
mean difference threshold – the difference between the peptide and the mean
conservation scores were accumulated for each binding peptide along the protein.
The total difference below the mean was subtracted by the total difference above.
A positive result indicates a ‘YES’ (see the Mean_Diff column in S3 Supporting
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Information); and 3) cumulative counts of the binding peptide conservation
scores per protein – proteins were ordered in ascending cumulative counts i.e.
from least to the most conserved. The length of the protein is a factor as there is a
positive correlation between the number of binding peptides and length of the
protein. The cumulative count was divided by the length of the protein prior to
ordering. The median cumulative count was used as the threshold for the binary
classification i.e. ‘YES’ if below and ‘NO’ if above threshold. Note that
homologous proteins with a 50% identity were also tested but provided less
accurate classifications. Also, some benchmark proteins had as few as three
homologous proteins when using 90% identity. Incorrect choices or an
inappropriate number of homologs could be a potential source for classification
errors.
Comparison prediction programs




(TMHMM); and http://phobius.binf.ku.dk/instructions.html (Phobius).
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S1 Supporting Information. Provides background information on T-cell
epitope prediction and machine learning algorithms used in the study.
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S2 Supporting Information. Contains a detailed compilation of proteins used
in the benchmark dataset.
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